DURVALUMAB OLAPARIB

Brand name:

• Imfinzi® Lynparza®

Pharmaceutical company:

ASTRAZENECA PTY LTD

Condition/indication:
(therapeutic use)

• Advanced, metastatic or recurrent endometrial cancer

PBAC Submission type:

Change to existing listing (Category 2)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – November 2024

Related medicines:

--

Submission received for:

November 2024 PBAC meeting

Opportunity for consumer comment:

Open 31/07/2024 and close 25/09/2024 (see PBS Website)

PBAC meeting:

Held on 06/11/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

16/04/2025

5Lodgement of required documentation:

Has not yet commenced

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---